Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-02-19 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, which is a report of a foreign private issuer submitted to the SEC. The content is an investor relations press release announcing that the drug Tasigna has received FDA priority review for a new indication. The document includes detailed clinical trial results, regulatory status updates, and safety information about the drug. It is not a full financial report, audit report, or earnings release. It is also not a management or board change announcement, nor a voting result or capital change. The document is a regulatory announcement providing material information to investors about a significant regulatory development and clinical trial data. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2010-02-19 English
SC 13G/A
Major Shareholding Notification
2010-02-16 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, a foreign private issuer, with the SEC. It contains a detailed report including financial highlights, operational review, product pipeline, corporate citizenship, governance, compensation, and consolidated financial statements. The content covers the full year 2009 results, including net sales, operating income, net income, and other comprehensive financial data. The length is substantial (15,000 characters) and the document includes actual financial statements and detailed management discussion. Form 6-K is typically used by foreign private issuers to report material information between annual reports (20-F). Given the comprehensive financial data and management discussion, this filing corresponds to an Interim / Quarterly Report (IR) type, as it is a periodic report shorter than a full fiscal year annual report but contains substantive financial data and analysis. It is not an announcement or certification, nor a simple regulatory filing. Therefore, the best classification is Interim / Quarterly Report (IR).
2010-02-09 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing Novartis gaining exclusive rights to Debio 025, an antiviral agent in Phase IIb development. It includes details about the drug, clinical trial results, and the licensing agreement. There are no financial statements or detailed financial analysis present. The document is primarily an announcement of a corporate development and licensing agreement, typical of a 6-K filing. It is not an annual or interim report, audit report, earnings release, or any other detailed financial or governance report. Given the nature of the document as a regulatory filing reporting material corporate news without detailed financial data, the appropriate classification is Regulatory Filings (RNS). The document length (11,039 characters) and content confirm it is not a brief announcement of a report publication (RPA) but a substantive regulatory announcement. Confidence is high due to clear identification of the form and content type.
2010-02-09 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, dated January 26, 2010, submitted to the SEC. It reports the company's financial results for the full year 2009 and the fourth quarter of 2009, including detailed financial figures such as net sales, operating income, net income, and earnings per share. It also discusses business highlights, product approvals, organizational productivity, and strategic priorities for 2010. The Form 6-K is a report of a foreign private issuer submitted under the Securities Exchange Act of 1934, typically used for current reports that are not annual or quarterly reports. The content includes comprehensive financial data and management commentary but is not a full annual report (10-K) or quarterly report (10-Q/IR). Given the nature of the filing and the detailed financial results presented, this document is best classified as a Regulatory Filing (RNS) because Form 6-Ks are considered current reports and do not fit the categories of Annual Report (10-K) or Interim/Quarterly Report (IR). The document is not a simple announcement or certification but a substantive report filed on Form 6-K, which is a regulatory filing category.
2010-01-26 English
20-F
Annual Report FY 2009
2010-01-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.